检索结果-南通市图书馆

Intranasal Immunization Using CTA1-DD as a Muco.al Adjuvant for an Inactivated Influenza Vaccine

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Biomedical and Environmental Sciences 2019年第7期32卷 531-540页

作者： FAN Xue Ting WANG Yun Long SU Qiu Dong QIU Feng YI Yao JIA Zhi Yuan WANG Da Yan QIN Kun ZOU Ye Ning BI Sheng Li SHEN Li Ping National Institute for Viral Disease co.trol and Prevention Chinese Center for Disease Control and Prevention Beijing 102206 China Henan Bioengineering Research Center Zhengzhou 4500466 Henan China sinovac biotech co. Ltd. Beijing 100085 China

Objective To evaluate the effect of intranasal immunization with CTA1-DD as muco.al adjuvant co.bined with H3N2 split vaccine. Methods Mice were immunized intranasally with PBS(negative co.trol), or H3N2 split vaccine(3 μg/mouse) alone, or CTA1-DD(5 μg/mouse) alone, or H3N2 split vaccine(3 μg/mouse) plus CTA1-DD(5 μg/mouse). Positive co.trol mice were immunized intramuscularly with H3N2 split vaccine(3 μg/mouse) and alum adjuvant. All the mice were immunized twice, two weeks apart. Then sera and muco.al lavages were co.lected. The specific HI titers, IgM, IgG, IgA, and IgG subtypes were examined by ELISA. IFN-γ and IL-4 were test by ELISpot. In addition, two weeks after the last immunization, surivival after H3N2 virus lethal challenge was measured. Results H3N2 split vaccine formulated with CTA1-DD co.ld elicit higher Ig M, Ig G and hemagglutination inhibition titers in sera. Furthermore, using CTA1-DD as adjuvant significantly improved muco.al secretory Ig A titers in bronchoalveolar lavages and vaginal lavages. Meanwhile this muco.al adjuvant co.ld enhance Th-1-type responses and induce protective hemagglutination inhibition titers. Notably, the addition of CTA1-DD to split vaccine provided 100% protection against lethal infection by the H3N2 virus. co.clusion CTA1-DD co.ld promote muco.al, humoral and cell-mediated immune responses, which supports the further development of CTA1-DD as a muco.al adjuvant for muco.al vaccines.

关键词： Adjuvants H3N2 Influenza Muco.al immunization Split vaccine

Immunogenicity and Safety of Homologous Booster Doses of co.onaVac co.ID-19 Vaccine in Elderly Individuals Aged 60 Years and Older:A Dosing Interval Study—Yunnan Province,China,2021–2022

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

China CDC weekly 2023年第6期5卷 125-130,I0008-I0012页

作者： Haitao Yang Xing Meng Tingyu Zhuang Cangning Wang Zhongliang Yang Taotao Zhu Mei Li Yan Zheng Qianhui Wu Yaling Hu Hongjie Yu Xiaoqiang Liu Gang Zeng Yunnan Provincial Center for Disease co.trol and Prevention Kunming CityYunnan ProvinceChina sinovac biotech co. Ltd.Beijing MunicipalityChina School of Public Health Fudan UniversityKey Laboratory of Public Health SafetyMinistry of EducationShanghai MunicipalityChina Yongde co.nty Center for Disease co.trol and Prevention Lincang CityYunnan ProvinceChina sinovac Life Sciences Beijing MunicipalityChina

Summary What is already known about this topic?Neutralization levels induced by inactivated vaccines rapidly wane after primary immunization,and a homologous booster can recall specific immune memory,resulting in a re... 详细信息

关键词： co.centration. doses remarkable

A third high dose of inactivated co.ID-19 vaccine induces higher neutralizing antibodies in humans against the Delta and Omicron variants:a Randomized,Double-Blinded Clinical Trial

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Science China(Life Sciences) 2022年第8期65卷 1677-1679页

作者： Yu Cao Xiaoli Wang Siqi Li Yuan Dong Yonghong Liu Jing Li Yanqing Zhao Yingmei Feng Department of Science and Technology Beijing Youan HospitalCapital Medical UniversityBeijing 100069China Beijing Center for Disease Prevention and co.trol Beijing 100013China sinovac biotech co LtdBeijingBeijing 100085China

Dear Editor,The current pandemic of co.onavirus disease 2019(co.ID-19),caused by infection with severe acute respiratory syndrome co.onavirus-2(SARS-co.V-2),has been ongoing for over 2 *** other viruses,SARS-co.V-2 co...

关键词： acute respiratory antibodies

Standardized neutralization antibody analytical procedure for clinical samples based on the AQbD co.cept

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第5期8卷 2078-2080页

作者： Jianyang Liu Yu Bai Mingchen Liu Dejiang Tan Jing Li Zhongfang Wang Zhenglun Liang Miao Xu Junzhi Wang Qunying Mao National Institutes for Food and Drug co.trol BeijingChina NHC Key Laboratory of Research on Quality and Standardization of biotech Products BeijingChina NMPA Key Laboratory for Quality Research and Evaluation of Biological Products BeijingChina sinovac Life Science co. Ltd.BeijingChina Guangzhou Laboratory GuangzhouGuangdong ProvinceChina

Dear Editor,Vaccination is an effective strategy for co.trolling the co.ID-19 pandemic and reducing the number of cases of hospitalization and deaths.1 Neutralizing antibody(Ntab)is one of the key indicators for evaluating the effectiveness of co.ID-19 vaccines.2 Over 40 co.ID-19 vaccines have been approved for emergency use,marketing,or marketing with co.ditions,and the available Ntab data from clinical trials have been published.

关键词： clinical QbD cases

An Immunoco.petent Patient with High Neutralizing Antibody Titers Who Shed co.ID-19 Virus for 169 days——China,2020

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

China CDC weekly 2021年第32期3卷 688-691,I0003-I0008页

作者： Li Li Siqi Li Yang Pan Ling Qin Siyuan Yang Dawei Tan Yaling Hu Maria Deloria Knoll Xiaoli Wang Linghang Wang Quanyi Wang Beijing Ditan Hospital Capital Medical UniversityBeijingChina Johns Hopkins Bloomberg School of Public Health BaltimoreMarylandUSA Beijing Center for Disease co.trol and Prevention BeijingChina Biomedical Information Center of Beijing YouAn Hospital Capital Medical UniversityBeijingChina sinovac biotech co LtdBeijingChina

Few reports are available about prolonged shedding of co.onavirus disease(co.ID-19)virus,also known as severe acute respiratory syndrome co.onavirus 2(SARS-co.-2),by immunoco.petent *** report a case of an infected,immunoco.petent person with 169 days of co.ID-19 virus shedding during which time he had two brief periods when he tested negative for co.ID-19 followed by again testing *** describe relevant clinical,immunological,and genomic *** found that co.tinuous and prolonged viral replication and infectivity existed in an immunoco.petent co.ID-19 patient,despite having high neutralizing antibody titers.

关键词： Antibody acute respiratory

Safety and Effectiveness of SA58 Nasal Spray Against co.ID-19 Infection in Medical Personnel:An Open-Label,Blank-co.trolled Study—Hohhot City,Inner Mongolia Autonomous Region,China,2022

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

China CDC weekly 2023年第10期5卷 218-222页

作者： Shujie Si Canrui Jin Jianping Li Yunlong Cao Biao Kan Feng Xue Xiaoliang Sunney Xie Liang Fang Gang Zeng Shuo Zhang Yaling Hu Xiaoping Dong Pharmacy Department Inner Mongolia Fourth HospitalHohhot CityInner Mongolia Autonomous RegionChina Clinical Research and Development Department Sinovac Biotech Co.Ltd.BeijingChina Biomedical Pioneering Innovation Center(BIOPIC) Peking UniversityBeijingChina Changping Laboratory BeijingChina State Key Laboratory for Infectious Disease Prevention and co.trol NHC Key Laboratory of Medical Virology and Viral DiseasesNational Institute for Viral Disease Control and PreventionChinese Center for Disease Control and PreventionBeijingChina Research and Development Department Sinovac Life Sciences Co.Ltd.BeijingChina Inner Mongolia Blood Center Hohhot CityInner Mongolia Autonomous RegionChina Center for Biosafety Mega-Science Chinese Academy of SciencesWuhan CityHubei ProvinceChina China Academy of Chinese Medical Sciences BeijingChina Shanghai Institute of Infectious Diseases and Biosafety ShanghaiChina

Summary What is already known about this topic?The active ingredient of the SA58 Nasal Spray is a broad-spectrum neutralizing antibody with a high neutralizing capacity against different Omicron subvariants in vitro *** is added by this report?This study demonstrated the safety and effectiveness of SA58 Nasal Spray against co.onavirus disease 2019(co.ID-19)infection in medical personnel for the first *** are the implications for public health practice?This study provides an effective approach for the public to reduce their risk of co.ID-19 *** findings of this research have the potential to significantly reduce the risk of infection and limit human-to-human transmission in the event of a co.ID-19 outbreak.

关键词： neutral co. Nasal

Antibody-dependent cellular cytotoxicity response to SARS-co.-2 in co.ID-19 patients

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2021年第10期6卷 3132-3141页

作者： Yuanling Yu Meiyu Wang Xiaoai Zhang Shufen Li Qingbin Lu Haolong Zeng Hongyan Hou Hao Li Mengyi Zhang Fei Jiang Jiajing Wu Ruxia Ding Zehua Zhou Min Liu Weixue Si Tao Zhu Hangwen Li Jie Ma Yuanyuan Gu Guangbiao She Xiaokun Li Yulan Zhang Ke Peng Weijin Huang Wei Liu Youchun Wang Division of HIV/AIDS and Sex-transmitted Virus Vaccines Institute for Biological Product ControlNational Institutes for Food and Drug Control(NIFDC)BeijingChina Graduate School of Peking Union Medical co.lege Chinese Academy of Medical SciencesPeking Union Medical CollegeBeijingChina State Key Laboratory of Pathogen and Biosecurity Beijing Institute of Microbiology and EpidemiologyBeijingChina State Key Laboratory of Virology Wuhan Institute of VirologyChinese Academy of SciencesWuhanHubeiChina Department of Laboratorial Science and Technology School of Public HealthPeking UniversityBeijingChina Department of Laboratory Medicine Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina sinovac biotech co. LtdBeijingChina Cansino biotech Inco.poration TianjinChina Stemirna Therapeutics LtdShanghaiChina Anhui Zhifeilongco. Biopharmaceutical co. LtdHefeiChina University of Chinese Academy of Sciences BeijingChina

Antibody-dependent cellular cytotoxicity(ADCC)responses to viral infection are a form of antibody regulated immune responses mediated through the Fc *** severe acute respiratory syndrome co.onavirus 2(SARS-co.-2)triggered ADCC responses co.tributes to co.ID-19 disease development is currently not well *** understand the potential co.relation between ADCC responses and co.ID-19 disease development,we analyzed the ADCC activity and neutralizing antibody response in 255 individuals ranging from asymptomatic to fatal infections over 1 year post *** was elicited by 10 days post-infection,peaked by 11-20 days,and remained detectable until 400 days *** general,patients with severe disease had higher ADCC ***,patients who had severe disease and reco.ered had higher ADCC activities than patients who had severe disease and ***,ADCC activities were mediated by a diversity of epitopes in SARS-co.-2-infected mice and induced to co.parable levels against SARS-co.-2 variants of co.cern(VOCs)(B.1.1.7,B.1.351,and P.1)as that against the D614G mutant in human patients and vaccinated *** study indicates anti-SARS-co.-2 ADCC as a major trait of co.ID-19 patients with various co.ditions,which can be applied to estimate the extra-neutralization level against co.ID-19,especially lethal co.ID-19.

关键词： patients ADCC Antibody

Factors Associated with SARS-co.-2 Repeat Positivity—Beijing,China,June–September 2020

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

China CDC weekly 2022年第5期4卷 88-95,I0006-I0010页

作者： Siqi Li Xiaoli Wang Li Li Yang Pan Siyuan Yang Dawei Tan Ying Shen Peng Yang Naor Bar-Zeev Yaling Hu Jacky MJennings Simin Li Linghang Wang Quanyi Wang Beijing Center for Disease Prevention and co.trol BeijingChina Department of International Health Johns Hopkins Bloomberg School of Public HealthBaltimoreMDUSA Beijing Municipal Key Laboratory of Clinical Epidemiology BeijingChina School of Public Health Capital Medical UniversityBeijingChina Emergency department of Infectious diseases Beijing Ditan HospitalCapital Medical UniversityBeijingChina Laboratory of Infectious Diseases Center of Beijing Ditan Hospital Capital Medical UniversityBeijingChina sinovac biotech co LtdBeijingChina Department of Pediatrics Johns Hopkins School of MedicineBaltimoreMDUSA Yiducloud(Beijing)Technology co. LtdBeijingChina

Introduction:Repeat positive severe acute respiratory syndrome co.onavirus 2(SARS-co.-2)following co.ID-19 initial viral clearance(repositivity)poses a public health management *** objective was to determine factors associated with neutralizing antibody(Nab)level and re-positivity among patients infected with a single strain ***:During a single strain SARS-co.-2 cluster in Beijing,China,longitudinal individual clinical,virological,and immunological data were co.lected from 368 infections from June 13 to September 22,*** associated with Nab level and re-positivity were analyzed using generalized estimating ***:A total of 353(96%)SARS-co.-2 infections had demographic,clinical,and laboratory data *** the 353 infections,55(15.5%)were re-positive,and blood draws were taken from 346 individuals(98.0%)during hospitalization and/or during the follow-up *** were milder for the seco.d-time admission for the re-positives,although 36.4%of re-positives presented with radiographic appearance of pneumonia *** to non-re-positive patients,NAb titers were lower among re-positives;NAb was positively associated with clinical *** from the lower respiratory tract manifested higher viral load than that from the upper respiratory *** analysis showed re-positivity was positively associated with being female[odd ratio(OR)=1.7,95%co.fidence interval(CI)1.1–2.8]and being agedco.clusions:NAb may be important for sustained viral *** respiratory tract infection was associated with higher viral load among all infections when co.pared to upper respiratory tract *** lower respiratory and intermittent upper respiratory viral shedding among co.ID-19 infections may occur.

关键词： sustained initially neutral

SARS-co.-2 variants:A co.tinuing threat to global health

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Pacific Journal of Tropical Medicine 2022年第1期15卷 1-3页

作者： Balamurugan Shanmugaraj Narach Khorattanakulchai Waranyoo Phoolcharoen Baiya Phytopharm co. LtdBangkok10250Thailand Research Unit for Plant-produced Pharmaceuticals Chulalongkorn UniversityBangkok10330Thailand Department of Pharmaco.nosy and Pharmaceutical Botany Faculty of Pharmaceutical SciencesChulalongkorn UniversityBangkok10330Thailand

co.onavirus disease 2019(co.ID-19)is an acute respiratory illness caused by severe acute respiratory syndrome co.onavirus 2(SARS-co.-2).co.ID-19 pandemic has an unprecedented impact on eco.omy,trade and human lifestyle *** the emergence of of SARS-co.-2,more than 266 million infections and 5260888 deaths were reported globally over the last two years[1].The scientific achievements particularly in last two years yielded effective vaccines against co.ID-19.A variety of platform technologies including protein subunit,viral vector,RNA,inactivated and DNA are being employed to develop effective *** date,vaccines that have been approved against co.ID-19 include the Pfizer BioNTech(mRNA vaccine),Oxford-AstraZeneca(viral vector vaccine),Moderna(mRNA vaccine),Janssen ***2.S(viral vector),Sinopharm,sinovac-co.onaVac,Bharat biotech’s co.axin(inactivated virus vaccines),*** of December 2021,over 8 billion doses of co.ID-19 vaccines have been administered globally[1].The details on the number of co.ID-19 co.firmed cases and global vaccination co.erage are provided in Figure 1.

关键词： Pfizer doses globally